Investment Analysts’ Recent Ratings Changes for Boston Scientific (BSX)

A number of research firms have changed their ratings and price targets for Boston Scientific (NYSE: BSX):

• 8/2/2026 – Boston Scientific was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/31/2026 – Boston Scientific had its “hold” rating reaffirmed by Argus.
• 7/30/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $85.00 to $70.00. They now have an “outperform” rating on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by UBS Group AG from $74.00 to $67.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $60.00 price target on the stock.
• 7/30/2026 – Boston Scientific was given a new $56.00 price target by Robert W. Baird.
• 7/30/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $70.00 to $66.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $55.00 to $50.00. They now have an “equal weight” rating on the stock.
• 7/30/2026 – Boston Scientific was given a new $60.00 price target by Leerink Partners.
• 7/30/2026 – Boston Scientific had its price target lowered by Citigroup Inc. from $70.00 to $61.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $57.00 price target on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by TD Cowen from $61.00 to $56.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $62.00 to $57.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Boston Scientific was given a new $60.00 price target by Stifel Nicolaus.
• 7/29/2026 – Boston Scientific had its price target lowered by BTIG Research from $65.00 to $60.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Boston Scientific had its “buy” rating reaffirmed by UBS Group AG. They now have a $74.00 price target on the stock, down from $95.00.
• 7/28/2026 – Boston Scientific had its “buy” rating reaffirmed by UBS Group AG. They now have a $74.00 price target on the stock, down from $95.00.
• 7/28/2026 – Boston Scientific had its “buy” rating reaffirmed by UBS Group AG. They now have a $74.00 price target on the stock, down from $95.00.
• 7/27/2026 – Boston Scientific had its price target lowered by Oppenheimer Holdings, Inc. from $90.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/25/2026 – Boston Scientific was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/16/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $64.00 to $62.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Boston Scientific had its price target lowered by Mizuho from $90.00 to $70.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $100.00 to $85.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Boston Scientific had its price target lowered by Needham & Company LLC from $77.00 to $57.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Boston Scientific was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 7/6/2026 – Boston Scientific was given a new $65.00 price target by Evercore Inc.
• 6/25/2026 – Boston Scientific had its price target lowered by Stifel Nicolaus from $75.00 to $65.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Boston Scientific had its price target lowered by Jefferies Financial Group Inc. from $100.00 to $67.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 204,322 shares of company stock valued at $9,939,221. Insiders own 0.34% of the company’s stock.

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.